Phase IIa, Dose-Finding Study of Ad5.F35-hGCC-PADRE Vaccine in Adults With Gastrointestinal Adenocarcinomas at Risk of Relapse Post Definitive Surgery and Standard Therapy
The purpose of this phase IIa study is to evaluate the safety and tolerability as well as cellular response of Ad5.F35-hGCC-PADRE vaccine delivered intramuscularly in patients with colorectal, pancreatic, gastric, or esophageal cancers who are at high risk of relapse without evidence of disease post definitive surgery and standard therapy.
Study ID: 19P.785
Trial Phase: Phase II
Trial Sponsor: Thomas Jefferson University
Therapies Used in This Trial: Ad5.F35-hGCC-PADRE